Adjuvant Osimertinib Extends DFS in Localized NSCLC Adjuvant Osimertinib Extends DFS in Localized NSCLC

Adjuvant therapy with osimertinib yielded a nearly 80% reduction in the risk of disease recurrence or death in patients with stage IB-IIIA non – small cell lung cancer with EGFR mutations in the ADAURA   trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news